4‐Hydroxytamoxifen induces a noncanonical ferroptosis in lung adenocarcinoma by targeting AKR1B10
Open Access
- 8 September 2026
- journal article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (9)
Abstract
Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, and current therapies are limited by drug resistance and toxicity. Ferroptosis offers an attractive strategy for cancer therapy, but classical ferroptosis is iron‑dependent. Repurposing approved drugs offers a rapid strategy to identify novel anti‑LUAD agents, yet the mechanism by which 4‑Hydroxytamoxifen (4‑OHT) exerts estrogen receptor–independent anti‑tumour effects remains unclear. Methods: We performed a drug repurposing screen of 950 endogenous metabolites in LUAD cells. Anti‑tumour activity was validated in vitro and in vivo using LUAD cell lines and mouse models. Target identification and mechanistic studies employed LiP‑MS, pull‐down SPR, CETSA, metabolomics, and enzyme activity assays. Clinical relevance was assessed via tissue microarrays and TCGA analysis. Drug synergy was quantified using the Chou–Talalay method. Results: 4‑OHT inhibited LUAD cell proliferation with IC 50 values of 3.86 ± 0.26 µM to 13.58 ± 0.55 µM independent of estrogen receptor. It triggered noncanonical ferroptosis characterised by GSH depletion (reduced by about 60%), GPX4 downregulation, lipid peroxidation (about 2.5‐fold increase), and iron independence. Mechanistically, 4‑OHT directly bound AKR1B10 (K D (M) was 7.98e‐06) and inhibited its enzymatic activity, leading to ACC1 degradation, lipid deficiency, and accumulation of toxic lipid‑derived carbonyls. AKR1B10 knockout abolished 4‑OHT‑induced cell death, while rescue restored sensitivity. Nanatinostat similarly targeted AKR1B10 and induced the same cell death modality. AKR1B10 upregulation in LUAD tissues correlated with reduced overall survival rates. Conclusion: This study demonstrates that 4‑OHT directly inhibits AKR1B10 enzymatic activity to induce a noncanonical ferroptosis in LUAD. AKR1B10 overexpression correlates with poor prognosis and chemoresistance in LUAD patients. Nonetheless, AKR1B10 inhibition warrants further investigation as a therapeutic strategy. Highlights: 4‑OHT directly inhibits AKR1B10 enzymatic activity to induce noncanonical ferroptosis in LUAD. AKR1B10 sustains LUAD survival by stabilising ACC1 and detoxifying reactive carbonyl species (RCSs). Nanatinostat similarly targets AKR1B10 and elicits the same cell death modality. AKR1B10 overexpression correlates with poor prognosis and chemoresistance in LUAD.Keywords
Funding Information
- National Natural Science Foundation of China (82273258)
- National Natural Science Foundation of China (81902346)
- National Natural Science Foundation of China (82270108)
- Key Research and Development Program of Jiangxi Province (20232BBG70022)
- Key Research and Development Program of Jiangxi Province (20243BBI91019)
- Natural Science Foundation of Jiangxi Province
This publication has 63 references indexed in Scilit:
- Aromatic amino acid metabolism shapes autophagy-mediated adaptation to iron deprivation in glioblastoma cellsBioMetals, 2026
- NKX2‐1 Restricts the Growth and Metastasis of Lung Squamous Cell Carcinoma Through Transcriptive Suppression of AKR1B10Journal of Biochemical and Molecular Toxicology, 2025
- Interplay of cGAS-STING and ferroptosis: crosstalk, molecular mechanisms, and therapeutic prospectsArchives of Toxicology, 2025
- Glycodiversification of gentamicins through in vivo glycosyltransferase swapping enabled the creation of novel hybrid aminoglycoside antibiotics with potent activity and low ototoxicityActa Pharmaceutica Sinica B, 2024
- Repurposing lansoprazole to alleviate metabolic syndrome via PHOSPHO1 inhibitionActa Pharmaceutica Sinica B, 2024
- Deubiquitinase OTUD5 as a Novel Protector against 4‐HNE‐Triggered Ferroptosis in Myocardial Ischemia/Reperfusion InjuryAdvanced Science, 2023
- A Large‐Scale Multicenter Study Validates Aldo‐Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular CarcinomaHepatology, 2019
- AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cellsMolecular Carcinogenesis, 2018
- Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compoundsMolecular Carcinogenesis, 2016
- Tamoxifen inhibits growth of oestrogen receptor-negative A549 cellsBiochemical Pharmacology, 1994